Professional Documents
Culture Documents
Source: Company data, RHB P/E (x) P/B (x) ROAE Yield (%)
Dec-23F
9.8 Dec-23F
0.7 (%)0.1 Dec-23F
0.0
See important disclosures at the end of this report
1
Market Dateline / PP 19489/05/2019 (035080) 5.8 0.9 0.2 0.1
Plantation Regional Sector Update
11 April 2023 Agriculture | Plantation
CPO prices (third month futures) fell 19% to a low of MYR3,512 on 24 Mar in the span
of three weeks, before recovering slightly to the current levels of MYR3,794. We believe the
decline was mainly due to external circumstances this time around, dragged down by the
bank crises in the US, the USD weakness and global commodity price weakness including
that of crude oil, soybean oil and rapeseed oil, amongst others. Crude oil prices fell 13% in
the same period, while soybean oil and rapeseed oil prices contracted by by 12% and 14%.
While the fears of a global recession are still intact, the US government has been actively
reassuring the public that it is safeguarding against further banking crises happening.
Source: Bloomberg
We believe supply risks are easing, with the conclusion of La Nina in mid-March.
While there have been negative effects from the drought on soybean harvests in Argentina,
Brazil’s output is expected to remain abundant, resulting in a projected net production rise
of 5.5% YoY in 2023F in South America. Total global soybean output, however, is expected
to rise by a smaller 3% YoY in 2023F. Despite the smaller soybean output growth, we
highlight that rapeseed and canola output growth in 2023F is expected to more than offset
this, with growth projected at 18% YoY. On a net basis, output growth for the 10 oilseeds is
projected at 17% YoY, resulting in relatively comfortable stock levels and an improved
stock/usage ratio. What this means for vegetable oil supply is that there should be ample
supply of seed oils this year, with rapeseed and sunflower oil supply projected to grow 8%
YoY this year and palm oil at 4% YoY.
Figure 3: Soybean output affected by La Nina in South Figure 4: Other oilseeds output growth is still strong
America
Figure 5: Eight vegetable oil composite benefitting from Figure 6: Palm oil output is anticipated to recover in 2023F
sunflower and rapeseed oil production growth
In Malaysia, labour shortages may be a thing of the past soon, but what about the
impact of under-fertilisation? We understand labour shortages are close to being
resolved as most companies are now only having shortages of between 10-15%, with
expectations of this to be fully resolved by 1H23. The Malaysian Government recently
approved another quota for the entry of 20,970 workers for the plantation sector under the
Foreign Worker Employment Relaxation Plan (FWERP) as of 18 Mar. With this, Oil World
expects Malaysia to produce 4.5% more palm oil in 2023F. We believe production may
come in lower than this, however, as we expect some impact from under-fertilisation of crops
over the last 1-2 years to be seen in 2023. As such, we believe Malaysia may only produce
2-3% YoY more output in 2023F.
Weather remains the biggest risk to supply. According to the Australian Bureau of
Meteorology, El Nino could potentially return towards 3Q23, with the probability now at 50%.
However, the US National Oceanic and Atmospheric Association’s (NOAA) Climate
Prediction Centre has this probability at 67%. If this occurs and if it is a strong El Nino, this
would affect the peak cropping season for oil palm in 2H23, which would mean that the
global production output growth expectation of 4% may not pan out. This could also affect
productivity in 2024 and 2025, depending on how intense the El Nino is.
Figure 8: El Nino probability
On the demand front, the CPO discount is not as attractive anymore. With the recent
pullback in prices, CPO is now trading at a smaller discount to SBO of USD258 per tonne
(from USD363 per tonne last month and the peak of USD820 in Nov 2022), albeit, still higher
than the historical discounts of USD100-150 per tonne. This could deem CPO not as
attractive anymore versus its competitive oils.
Figure 9: CPO prices tracked SBO prices closely since Nov Figure 10: CPO is trading at a USD258/tonne discount to SBO
2021 but have been diverging since May 2022 (from USD363/tonne last month)
2,200 2,500 1,000
2,000
800
1,800
2,000
600
1,600
1,500
1,400 400
1,200
200
1,000
1,000
-
800
500
600 (200)
400
- (400)
Dec-01
Dec-02
Dec-03
Dec-04
Dec-05
Dec-06
Dec-07
Dec-08
Dec-09
Dec-10
Dec-11
Dec-12
Dec-13
Dec-14
Dec-15
Dec-16
Dec-17
Dec-18
Dec-19
Dec-20
Dec-21
Dec-22
Soyoil, USD/tonne CPO, USD/tonne Premium, USD (RHS) Soyoil, USD CPO, USD
800 50%
1,500
40%
600
1,000 30%
400 20%
500
10%
200
- 0%
YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD YTD
-
YTD '05YTD '07YTD '09YTD '11YTD '13YTD '15YTD '17YTD '19YTD '21YTD '23 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23
India's edible oil import India's palm oil import
China's palm oil import Palm oil's market share
Figure 13: China’s palm oil stocks are at 51.9% above the Figure 14: India’s palm oil stocks are at 18.8% above the
historical average as at Mar 2023 historical average as at Mar 2023
China Total Ending Stocks (MT) (2018-2023) India Total Ending Stocks (MT) (2018-2023)
1,300,000
900,000
800,000
1,100,000
700,000
900,000 600,000
500,000
700,000
400,000
500,000 300,000
200,000
300,000 100,000
0
100,000
2018 2019 2020 2021 2022 2023 2018 2019 2020 2021 2022 2023
While discretionary biofuel demand is unlikely to return... The POGO spread has
moderated slightly with the recent reduction in crude oil prices but remains positive, with
gas oil prices being USD19.90 per bbl (USD146 per tonne) more expensive than CPO. This
means that discretionary biodiesel will not return.
… mandated demand is still growing. Mandated demand, however, continues to grow. In
Brazil, the biodiesel mandate has been raised to B12 from Apr 2023 (from B10), while
Indonesia remains steadfast in its plan to raise its mandate further to B40 in 2024 (from B35
currently). We highlight, however, that while Indonesia has technically moved to a B35 blend
since Feb 2023, we believe production has yet to reflect these levels as yet – as Feb’s
biodiesel production was 54% below Dec 2022’s output.
Figure 15: Gas oil and CPO price gap is at -USD19.90/bbl Figure 16: Biodiesel production (+11% YoY) and distribution
in Indonesia (+13% YoY) in 2M23
In the longer term, the deforestation-free supply chain law will come into effect from
end-2024. Importers and exporters will then need to prove that the commodities (including
palm oil) that enter the EU are not produced from deforestation and forest degradation, with
the cut-off point being after 31 Dec 2020. Non-compliance will result in a fine of at least 4%
of the operators or trader's annual turnover in the member state(s) concerned. While we
understand that the integrated players under our coverage believe that they should not have
a problem complying with these regulations, the difficulty will come in proving that they are
compliant – as the requirements are extremely detailed and time-consuming. We believe
the EU may also find it difficult to ensure adherence to the regulations, given the many
member states and the subjectiveness of the matter. Currently, the large integrated planters
under our coverage have got quite significant revenue exposure to the EU, due to their
downstream plants located there.
Monthly statistics
March production grew by 2.8% MoM (-8.7% YoY). The MoM output growth came from
Sabah (+8.6%) and Sarawak (+6.6%), offset by West Malaysia (-1.4%), while the YoY
decline was from West Malaysia (-18.2%) and Sarawak (-4.9%), offset by Sabah (+12.7%).
States that experienced floods in March posted MoM declines – such as Johor (-8.0%) and
Negeri Sembilan (-3.6%) – while Sabah posted stronger MoM output despite the wet
weather. We should continue to see production rising in the months to come, although April’s
output could be hampered by festive holidays. In Jan 2023, Indonesia’s production was
flattish (+0.8% YoY) while exports jumped 35.2% YoY.
Exports rose 31.8% MoM (+16.0% YoY) in March after recording MoM export declines for
three months straight since last December. We believe the impact of Indonesia’s stricter
DMO export ratio and export quota suspension has now been reflected in the export market,
which resulted in importing countries switching back to favour Malaysia’s palm oil. On top
of that, the heightened demand due to the festive Ramadan season could also be one of
the factors that propelled Malaysia’s exports in March. We believe top importing countries
have been currently running down its excess inventory as end-March stock levels have
declined for China and India, albeit still high – at 52% (from 57% as at end-February) and
19% (from 30% as at end-February) above historical levels. Pakistan has also been using
up its excess inventory, currently at 9% above historical levels as at end-March (from 53%
above historical levels as at end-February). Bangladesh, on the other hand, replenished its
inventory as its stock levels rose to 46% above historical as at end-March, from 36% above
historical levels as at end-February.
Stronger exports resulted in inventory levels falling to 1.67m (-21.1% MoM and +13.6%
YoY). March’s annualised stock/usage ratio dropped to 8.6% (from 11.1% in February),
crossing below the 20-year historical average of 10%. We may see Malaysian PO stocks
continuing to decline, albeit slightly at end-April – taking into account the continued impact
of Indonesia’s DMO policy and export quota suspension (which will last until end-April).
Meanwhile, the Aidil Fitri holidays at end-April could drag the pick-up in output post wet
weather season. However, given the time it takes for major importing countries to run down
their inventory before restocking again, we believe a larger pick-up in demand is only likely
to come in 2H23.
Figure 19: Monthly CPO statistics
('000 tonnes) Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23
Opening stocks 1,518 1,473 1,643 1,522 1,646 1,773 2,095 2,317 2,408 2,288 2,197 2,268 2,120
Imports 85 77 58 59 131 172 132 69 47 65 145 53 40
Production 1,411 1,462 1,461 1,545 1,574 1,726 1,770 1,814 1,681 1,619 1,380 1,254 1,288
Total supply 3,014 3,012 3,162 3,126 3,350 3,671 3,997 4,200 4,136 3,972 3,722 3,574 3,448
Exports 1,282 1,073 1,376 1,194 1,325 1,300 1,423 1,504 1,521 1,474 1,137 1,128 1,486
Domestic use 260 296 263 286 252 276 257 288 326 302 317 327 289
Total off take 1,541 1,369 1,640 1,480 1,577 1,576 1,680 1,791 1,848 1,776 1,454 1,455 1,775
End-month stocks 1,473 1,643 1,522 1,646 1,773 2,095 2,317 2,408 2,288 2,197 2,268 2,120 1,673
Production YTD 3,802 5,264 6,725 8,270 9,844 11,570 13,340 15,154 16,835 18,453 1,380 2,634 3,922
MoM (%) 24.1 3.6 (0.1) 5.8 1.8 9.7 2.6 2.4 (7.3) (3.7) (14.7) (9.2) 2.8
YoY (%) (0.9) (4.3) (7.0) (3.8) 3.3 0.9 3.9 5.1 2.8 11.7 10.1 10.2 (8.7)
YTD (%) 3.9 1.5 (0.5) (1.1) (0.4) (0.2) 0.3 0.8 1.0 1.9 10.1 10.2 3.2
Exports YTD 3,548 4,621 5,998 7,192 8,517 9,817 11,240 12,744 14,265 15,739 1,137 2,265 3,751
MoM (%) 15.6 (16.3) 28.3 (13.3) 11.0 (1.9) 9.5 5.7 1.2 (3.1) (22.9) (0.8) 31.8
YoY (%) 7.8 (20.3) 8.5 (15.9) (5.5) 11.8 (11.7) 5.9 3.8 3.5 (1.8) 1.7 16.0
YTD (%) 17.0 5.5 6.2 1.8 0.6 1.9 (0.0) 0.6 1.0 1.2 (1.8) (0.1) 5.7
Stocks
MoM (%) (3.0) 11.5 (7.4) 8.1 7.7 18.2 10.6 3.9 (5.0) (4.0) 3.3 (6.5) (21.1)
YoY (%) 2.0 6.3 (3.0) 2.0 18.5 11.7 31.9 31.3 25.9 36.0 46.2 39.6 13.6
Source: Malaysian Palm Oil Board (MPOB), RHB
Figure 20: CPO inventory is at 1.67m tonnes Figure 21: Malaysia’s CPO production (+3.2% YoY in YTD-
Mar 2023)
8,000 3,500,000 2,100,000 Tonnes
7,000 3,000,000
1,900,000
6,000
2,500,000
5,000 1,700,000
2,000,000
4,000 1,500,000
1,500,000
3,000
1,000,000 1,300,000
2,000
0 0
900,000
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 2019 2020
Stocks, tonnes (RHS) CPO Price, MYR (LHS) 2021 2022 2023
Figure 22: Malaysia's monthly palm oil exports (+5.7% YoY in Figure 23: Indonesia's monthly palm oil exports (+35.2% YoY
YTD-Mar 2023) in YTD-Jan 2023)
Tonnes
2,000,000
5
1,800,000
4.5
4
1,600,000
3.5
Exports (mMT)
3
1,400,000 2.5
2
1,200,000 1.5
1
1,000,000 0.5
0
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
800,000
2019 2020 2021 2022
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019 2020 2021
2022 2023
Source: MPOB Source: Association of Indonesian Palm Oil Producers (GAPKI)
Risks
The main downside risks to our outlook include:
i. Russia-Ukraine war being prolonged and extended into other territories;
ii. Significant changes in the crude oil price trend that may result in changes in biodiesel
mandates;
iii. Weather abnormalities resulting in an oversupply or undersupply of vegetable oils;
iv. Significant changes in the demand for vegetable oils, caused by changes in economic
cycles or price dynamics;
v. Worsening labour situation in Malaysia causing production to be affected negatively;
vi. Revision in Indonesia’s tax structure and trade policies;
vii. Worsening of the COVID-19 pandemic;
viii. More ESG issues pinpointed for listed companies.
Figure 24: Effective CPO prices in Indonesia (post-change in the levy tax rate in mid-Nov 2022)
CPO price
at
MYR/tonne 4,500 4,400 4,300 4,200 4,100 4,000 3,900 3,800 3,700 3,600 3,500 3,400 3,300 3,200 3,100 3,000
CPO Price
(USD) 1,017 994 972 949 927 904 881 859 836 814 791 768 746 723 701 678
Levy Rate
(USD) 105 105 100 100 95 95 95 90 90 85 85 75 75 65 65 55
Levy Rate
(MYR) 465 465 443 443 420 420 420 398 398 376 376 332 332 288 288 243
Export Tax
(USD) 148 148 124 124 74 74 74 52 52 33 33 18 18 3 3 -
Export Tax
(MYR) 655 655 549 549 327 327 327 230 230 146 146 80 80 13 13 -
Effective
Indo Price 3,380 3,280 3,309 3,209 3,352 3,252 3,152 3,172 3,072 3,078 2,978 2,988 2,888 2,899 2,799 2,757
West Malaysia – 225 210 195 180 165 150 135 120 105 90 75 60 45 30 15 -
Windfall tax (15%
above
MYR3,000/tonne)
East Malaysia – 150 135 120 105 90 75 60 45 30 15 - - - - - -
Windfall tax (15%
above
MYR3,500/tonne)
Export tax 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 8.0% 7.5% 7.0% 7.0% 6.5% 6.0%
Export tax
(MYR/tonne) 360 352 344 336 328 320 312 304 296 288 280 255 231 224 201.5 180
Effective West
Malaysia price 3,915 3,838 3,761 3,684 3,607 3,530 3,453 3,376 3,299 3,222 3,145 3,085 3,024 2,946 2,883.50 2,820
(MYR/tonne)
Effective East
Malaysia price 3,990 3,913 3,836 3,759 3,682 3,605 3,528 3,451 3,374 3,297 3,220 3,145 3,069 2,976 2,898.50 2,820
(MYR/tonne)
Source: RHB
EV/ha (USD)
50,000
45,000
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
-
Source: RHB
Wilmar WIL SP 19,470 Buy 4.15 4.65 10.3 9.9 0.9 104.0% 4.0% 9.2% N/A
Bumitama Agri BAL SP 802 Neutral 0.62 0.66 5.8 6.5 0.9 10.3% 6.7% 15.7% 7,733
Golden Agri GGR SP 2,716 Buy 0.29 0.34 5.6 6.3 0.5 5.4% 3.6% 23.9% 12,166
First Resources FR SP 1,850 Neutral 1.57 1.60 8.0 8.1 1.3 -22.1% 6.3% 17.0% 9,573
PP London LSIP IJ 464 Neutral 1,015 1,010 7.6 8.1 0.6 Cash 5.3% 8.1% 2,683
Sumatra Indonesia
Astra Agro Lestari AALI IJ 1,062 Sell 8,225 7,230 9.8 10.4 0.7 7.0% 4.7% 6.8% 6,062
Regional Average 9.3 10.2 1.0 11,353
Note: Prices are as at 7 Apr 2023
Source: RHB, Bloomberg, Company data
RHB has issued this report for information purposes only. This report is intended for The use of any website to access this report electronically is done at the recipient’s own
circulation amongst RHB and its affiliates’ clients generally or such persons as may be risk, and it is the recipient’s sole responsibility to take precautions to ensure that it is free
deemed eligible by RHB to receive this report and does not have regard to the specific from viruses or other items of a destructive nature. This report may also provide the
investment objectives, financial situation and the particular needs of any specific person addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the
who may receive this report. This report is not intended, and should not under any content contained therein. Such addresses or hyperlinks (including addresses or
circumstances be construed as, an offer or a solicitation of an offer to buy or sell the hyperlinks to RHB own website material) are provided solely for the recipient’s
securities referred to herein or any related financial instruments. convenience. The information and the content of the linked site do not in any way form
part of this report. Accessing such website or following such link through the report or
This report may further consist of, whether in whole or in part, summaries, research, RHB website shall be at the recipient’s own risk.
compilations, extracts or analysis that has been prepared by RHB’s strategic, joint
venture and/or business partners. No representation or warranty (express or implied) This report may contain information obtained from third parties. Third party content
is given as to the accuracy or completeness of such information and accordingly providers do not guarantee the accuracy, completeness, timeliness or availability of any
investors should make their own informed decisions before relying on the same. information and are not responsible for any errors or omissions (negligent or otherwise),
regardless of the cause, or for the results obtained from the use of such content. Third
This report is not directed to, or intended for distribution to or use by, any person or party content providers give no express or implied warranties, including, but not limited
entity who is a citizen or resident of or located in any locality, state, country or other to, any warranties of merchantability or fitness for a particular purpose or use. Third party
jurisdiction where such distribution, publication, availability or use would be contrary to content providers shall not be liable for any direct, indirect, incidental, exemplary,
the applicable laws or regulations. By accepting this report, the recipient hereof (i) compensatory, punitive, special or consequential damages, costs, expenses, legal fees,
represents and warrants that it is lawfully able to receive this document under the laws or losses (including lost income or profits and opportunity costs) in connection with any
and regulations of the jurisdiction in which it is located or other applicable laws and (ii) use of their content.
acknowledges and agrees to be bound by the limitations contained herein. Any failure
to comply with these limitations may constitute a violation of applicable laws. The research analysts responsible for the production of this report hereby certifies that
the views expressed herein accurately and exclusively reflect his or her personal views
All the information contained herein is based upon publicly available information and and opinions about any and all of the issuers or securities analysed in this report and
has been obtained from sources that RHB believes to be reliable and correct at the were prepared independently and autonomously. The research analysts that authored
time of issue of this report. However, such sources have not been independently this report are precluded by RHB in all circumstances from trading in the securities or
verified by RHB and/or its affiliates and this report does not purport to contain all other financial instruments referenced in the report, or from having an interest in the
information that a prospective investor may require. The opinions expressed herein company(ies) that they cover.
are RHB’s present opinions only and are subject to change without prior notice. RHB
is not under any obligation to update or keep current the information and opinions The contents of this report is strictly confidential and may not be copied, reproduced,
expressed herein or to provide the recipient with access to any additional information. published, distributed, transmitted or passed, in whole or in part, to any other person
Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, without the prior express written consent of RHB and/or its affiliates. This report has
as to the adequacy, accuracy, reliability, fairness or completeness of the information been delivered to RHB and its affiliates’ clients for information purposes only and upon
and opinion contained in this report. Neither RHB (including its officers, directors, the express understanding that such parties will use it only for the purposes set forth
associates, connected parties, and/or employees) nor does any of its agents accept above. By electing to view or accepting a copy of this report, the recipients have agreed
any liability for any direct, indirect or consequential losses, loss of profits and/or that they will not print, copy, videotape, record, hyperlink, download, or otherwise
damages that may arise from the use or reliance of this research report and/or further attempt to reproduce or re-transmit (in any form including hard copy or electronic
communications given in relation to this report. Any such responsibility or liability is distribution format) the contents of this report. RHB and/or its affiliates accepts no
hereby expressly disclaimed. liability whatsoever for the actions of third parties in this respect.
Whilst every effort is made to ensure that statement of facts made in this report are The contents of this report are subject to copyright. Please refer to Restrictions on
accurate, all estimates, projections, forecasts, expressions of opinion and other Distribution below for information regarding the distributors of this report. Recipients
subjective judgments contained in this report are based on assumptions considered to must not reproduce or disseminate any content or findings of this report without the
be reasonable and must not be construed as a representation that the matters referred express permission of RHB and the distributors.
to therein will occur. Different assumptions by RHB or any other source may yield
substantially different results and recommendations contained on one type of research The securities mentioned in this publication may not be eligible for sale in some states
product may differ from recommendations contained in other types of research. The or countries or certain categories of investors. The recipient of this report should have
performance of currencies may affect the value of, or income from, the securities or regard to the laws of the recipient’s place of domicile when contemplating transactions
any other financial instruments referenced in this report. Holders of depositary receipts in the securities or other financial instruments referred to herein. The securities
backed by the securities discussed in this report assume currency risk. Past discussed in this report may not have been registered in such jurisdiction. Without
performance is not a guide to future performance. Income from investments may prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings
fluctuate. The price or value of the investments to which this report relates, either or qualifications may apply based on geographical location of the person or entity
directly or indirectly, may fall or rise against the interest of investors. receiving this report.
This report may contain comments, estimates, projections, forecasts and expressions The term “RHB” shall denote, where appropriate, the relevant entity distributing or
of opinion relating to macroeconomic research published by RHB economists of which disseminating the report in the particular jurisdiction referenced below, or, in every
should not be considered as investment ratings/advice and/or a recommendation by other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related
such economists on any securities discussed in this report. companies.
This report does not purport to be comprehensive or to contain all the information that a RESTRICTIONS ON DISTRIBUTION
prospective investor may need in order to make an investment decision. The recipient of
this report is making its own independent assessment and decisions regarding any Malaysia
securities or financial instruments referenced herein. Any investment discussed or This report is issued and distributed in Malaysia by RHB Investment Bank Berhad
recommended in this report may be unsuitable for an investor depending on the investor’s (“RHBIB”). The views and opinions in this report are our own as of the date hereof and
specific investment objectives and financial position. The material in this report is general is subject to change. If the Financial Services and Markets Act of the United Kingdom
information intended for recipients who understand the risks of investing in financial or the rules of the Financial Conduct Authority apply to a recipient, our obligations
instruments. This report does not take into account whether an investment or course of owed to such recipient therein are unaffected. RHBIB has no obligation to update its
action and any associated risks are suitable for the recipient. Any recommendations opinion or the information in this report.
contained in this report must therefore not be relied upon as investment advice based on
the recipient's personal circumstances. Investors should make their own independent Thailand
evaluation of the information contained herein, consider their own investment objective, This report is issued and distributed in the Kingdom of Thailand by RHB Securities
financial situation and particular needs and seek their own financial, business, legal, tax (Thailand) PCL, a licensed securities company that is authorised by the Ministry of
and other advice regarding the appropriateness of investing in any securities or the Finance, regulated by the Securities and Exchange Commission of Thailand and is a
investment strategies discussed or recommended in this report. member of the Stock Exchange of Thailand. The Thai Institute of Directors Association
has disclosed the Corporate Governance Report of Thai Listed Companies made
12
Market Dateline / PP 19489/05/2019 (035080)
pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB 3. None of RHBIB’s staff or associated person serve as a director or board member*
Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate of the subject company(ies) covered in this report
Governance Report of Thai Listed Companies. *For the avoidance of doubt, the confirmation is only limited to the staff of research
department
Indonesia 4. RHBIB did not receive compensation for investment banking or corporate finance
This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This services from the subject company in the past 12 months.
research does not constitute an offering document and it should not be construed as 5. RHBIB did not receive compensation or benefit (including gift and special cost
an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, arrangement e.g. company/issuer-sponsored and paid trip) in relation to the
in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any production of this report.
Indonesian resident in a manner which constitutes a public offering under Indonesian
laws and regulations must comply with the prevailing Indonesian laws and regulations. Thailand
Save as disclosed in the following link RHB Research conflict disclosures - Apr 2023
Singapore and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
This report is issued and distributed in Singapore by RHB Bank Berhad (through its 1. RHB Securities (Thailand) PCL does not have a financial interest in the securities
Singapore branch) which is an exempt capital markets services entity and an exempt or other capital market products of the subject company(ies) covered in this report.
financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad 2. RHB Securities (Thailand) PCL is not a market maker in the securities or capital
(through its Singapore branch) may distribute reports produced by its respective market products of the subject company(ies) covered in this report.
foreign entities, affiliates or other foreign research houses pursuant to an arrangement 3. None of RHB Securities (Thailand) PCL’s staff or associated person serve as a
under Regulation 32C of the Financial Advisers Regulations. Where the report is director or board member* of the subject company(ies) covered in this report
distributed in Singapore to a person who is not an Accredited Investor, Expert Investor 1. *For the avoidance of doubt, the confirmation is only limited to the staff of research
or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts department
legal responsibility for the contents of the report to such persons only to the extent 4. RHB Securities (Thailand) PCL did not receive compensation for investment
required by law. Singapore recipients should contact RHB Bank Berhad (through its banking or corporate finance services from the subject company in the past 12
Singapore branch) in respect of any matter arising from or in connection with the report. months.
5. RHB Securities (Thailand) PCL did not receive compensation or benefit (including
United States gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in
This report was prepared by RHB is meant for distribution solely and directly to “major” relation to the production of this report.
U.S. institutional investors as defined under, and pursuant to, the requirements of Rule
15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the Indonesia
“Exchange Act”) via a registered U.S. broker-dealer as appointed by RHB from time to Save as disclosed in the following link RHB Research conflict disclosures - Apr 2023
time. Accordingly, any access to this report via Bursa Marketplace or any other and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:
Electronic Services Provider is not intended for any party other than “major” US 1. PT RHB Sekuritas Indonesia and its investment analysts, does not have any
institutional investors (via a registered U.S broker-dealer), nor shall be deemed as interest in the securities of the subject company(ies) covered in this report.
solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the For the avoidance of doubt, interest in securities include the following:
United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB a) Holding directly or indirectly, individually or jointly own/hold securities or
does not offer brokerage services to U.S. persons. Any order for the purchase or sale entitled for dividends, interest or proceeds from the sale or exercise of the
of all securities discussed herein must be placed with and through a registered U.S. subject company’s securities covered in this report*;
broker-dealer as appointed by RHB from time to time as required by the Exchange Act b) Being bound by an agreement to purchase securities or has the right to
Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. transfer the securities or has the right to pre subscribe the securities*.
broker-dealer during the issuance of this report. This report is confidential and not c) Being bound or required to buy the remaining securities that are not
intended for distribution to, or use by, persons other than the recipient and its subscribed/placed out pursuant to an Initial Public Offering*.
employees, agents and advisors, as applicable. Additionally, where research is d) Managing or jointly with other parties managing such parties as referred to in
distributed via Electronic Service Provider, the analysts whose names appear in this (a), (b) or (c) above.
report are not registered or qualified as research analysts in the United States and are 2. PT RHB Sekuritas Indonesia is not a market maker in the securities or capital
not associated persons of any registered U.S. broker-dealer as appointed by RHB market products of the subject company(ies) covered in this report.
from time to time and therefore may not be subject to any applicable restrictions under 3. None of PT RHB Sekuritas Indonesia’s staff** or associated person serve as a
Financial Industry Regulatory Authority (“FINRA”) rules on communications with a director or board member* of the subject company(ies) covered in this report.
subject company, public appearances and personal trading. Investing in any non-U.S. 4. PT RHB Sekuritas Indonesia did not receive compensation for investment banking
securities or related financial instruments discussed in this research report may or corporate finance services from the subject company in the past 12 months.
present certain risks. The securities of non-U.S. issuers may not be registered with, or 5. PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including
be subject to the regulations of, the U.S. Securities and Exchange Commission. gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in
Information on non-U.S. securities or related financial instruments may be limited. relation to the production of this report:
Foreign companies may not be subject to audit and reporting standards and regulatory Notes:
requirements comparable to those in the United States. The financial instruments *The overall disclosure is limited to information pertaining to PT RHB Sekuritas
discussed in this report may not be suitable for all investors. Transactions in foreign Indonesia only.
markets may be subject to regulations that differ from or offer less protection than **The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.
those in the United States.
Singapore
DISCLOSURE OF CONFLICTS OF INTEREST Save as disclosed in the following link RHB Research conflict disclosures - Apr 2023
and to the best of our knowledge, the Singapore Research department of RHB Bank
RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and Berhad (through its Singapore branch) hereby declares that:
associated companies, (“RHBIB Group”) form a diversified financial group, 1. RHB Bank Berhad, its subsidiaries and/or associated companies do not make a
undertaking various investment banking activities which include, amongst others, market in any issuer covered by the Singapore research analysts in this report.
underwriting, securities trading, market making and corporate finance advisory. 2. RHB Bank Berhad, its subsidiaries and/or its associated companies and its
analysts do not have a financial interest (including a shareholding of 1% or more)
As a result of the same, in the ordinary course of its business, any member of the in the issuer covered by the Singapore research analysts in this report.
RHBIB Group, may, from time to time, have business relationships with, hold any 3. RHB Bank Berhad’s Singapore research staff or connected persons do not serve
positions in the securities and/or capital market products (including but not limited to on the board or trustee positions of the issuer covered by the Singapore research
shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own analysts in this report.
account or the account of its customers or perform and/or solicit investment, advisory 4. RHB Bank Berhad, its subsidiaries and/or its associated companies do not have
or other services from any of the subject company(ies) covered in this research report. and have not within the last 12 months had any corporate finance advisory
relationship with the issuer covered by the Singapore research analysts in this
While the RHBIB Group will ensure that there are sufficient information barriers and report or any other relationship that may create a potential conflict of interest.
internal controls in place where necessary, to prevent/manage any conflicts of interest 5. RHB Bank Berhad’s Singapore research analysts, or person associated or
to ensure the independence of this report, investors should also be aware that such connected to it do not have any interest in the acquisition or disposal of, the
conflict of interest may exist in view of the investment banking activities undertaken by securities, specified securities based derivatives contracts or units in a collective
the RHBIB Group as mentioned above and should exercise their own judgement investment scheme covered by the Singapore research analysts in this report.
before making any investment decisions. 6. RHB Bank Berhad’s Singapore research analysts do not receive any
compensation or benefit in connection with the production of this research report
In Singapore, investment research activities are conducted under RHB Bank Berhad or recommendation on the issuer covered by the Singapore research analysts.
(through its Singapore branch), and the disclaimers above similarly apply.
Analyst Certification
Malaysia The analyst(s) who prepared this report, and their associates hereby, certify that:
Save as disclosed in the following link RHB Research conflict disclosures - Apr 2023 (1) they do not have any financial interest in the securities or other capital market
and to the best of our knowledge, RHBIB hereby declares that: products of the subject companies mentioned in this report, except for:
1. RHBIB does not have a financial interest in the securities or other capital market
products of the subject company(ies) covered in this report. Analyst Company
2. RHBIB is not a market maker in the securities or capital market products of the - -
subject company(ies) covered in this report.
13
Market Dateline / PP 19489/05/2019 (035080)
(2) no part of his or her compensation was, is or will be directly or indirectly related to
the specific recommendations or views expressed in this report.
BANGKOK SINGAPORE
RHB Securities (Thailand) PCL RHB Bank Berhad (Singapore branch)
10th Floor, Sathorn Square Office Tower 90 Cecil Street
98, North Sathorn Road, Silom #04-00 RHB Bank Building
Bangrak, Bangkok 10500 Singapore 069531
Thailand Fax: +65 6509 0470
Tel: +66 2088 9999
Fax :+66 2088 9799
14
Market Dateline / PP 19489/05/2019 (035080)